Supplementary Figure 1 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers

figure

posted on 2023-07-19, 14:20 authored by Taraswi Mitra Ghosh, Suman Mazumder, Joshua Davis, Jyoti Yadav, Ayuba Akinpelu, Ahmed Alnaim, Harish Kumar, Razan Waliagha, Allison E. Church Bird, Soroush Rais-Bahrami, R. Curtis Bird, Panagiotis Mistriotis, Amarjit Mishra, Clayton C. Yates, Amit K. Mitra, Robert D. Arnold

Supplementary Fig. 1 shows Differentially expressed gene signature (DEGs) based on next gene sequencing (mRNA sequencing) for ARLow /mCRPC/NEPC (PC-3, PC-3M, DU145) vs ARHigh /mCSPC (LNCaP, VCAP, 22RV1) prostate cancer (PCa) cell lines and normal prostate cell lines RWPE1 and RWPE2. Volcano plots representing mRNA expression for all cell lines. (blue p<0.05 and gray>0.05) HeatMap representing Differentially Expressed Gene Signature (DEGs) for ARLow/mCRPC/NEPC (PC-3, PC-3M, DU145) vs ARHigh/mCSPC (LNCaP, VCAP, 22RV1) PCa and normal prostate cell lines RWPE1 and RWPE2 (FDR<0.05 and TOP-100).

Funding

N/A

History

ARTICLE ABSTRACT

The utilization of metronomic-like dosing regimens of topotecan alone and in combination with DTX resulted in the suppression of makers associated with EMT and stem-like cell populations in AVPC models. The identification of molecular signatures and their potential to serve as novel biomarkers for monitoring treatment efficacy and disease progression response to treatment efficacy and disease progression were achieved using bulk RNA-seq and single-cell-omics methodologies.